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Abstract
Transglutaminase 2 (TG2) is a hypoxia-responsive protein that is a calcium-activated transamidating enzyme, a GTPase and a
scaffolding/linker protein. Upon activation TG2 undergoes a large conformational change, which likely affects not only its
enzymatic activities but its non-catalytic functions as well. The focus of this study was on the role of transamidating activity,
conformation and localization of TG2 in ischemic cell death. Cells expressing a GTP binding deficient form of TG2 (TG2-
R580A) with high basal transamidation activity and a more extended conformation showed significantly increased cell death
in response to oxygen-glucose deprivation; however, targeting TG2-R580A to the nucleus abrogated its detrimental role in
oxygen-glucose deprivation. Treatment of cells expressing wild type TG2, TG2-C277S (a transamidating inactive mutant) and
TG2-R580A with Cp4d, a reversible TG2 inhibitor, did not affect cell death in response to oxygen-glucose deprivation. These
findings indicate that the pro-cell death effects of TG2 are dependent on its localization to the cytosol and independent of
its transamidation activity. Further, the conformational state of TG2 is likely an important determinant in cell survival and
the prominent function of TG2 in ischemic cell death is as a scaffold to modulate cellular processes.
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Introduction
Transglutaminase 2 (TG2) is a multifunctional protein which
plays a role in many different cellular processes including
differentiation, neuronal growth, inflammation, development,
wound healing [1] and hypoxic cell response [2]. In addition to
catalyzing calcium-dependent transamidation reactions, TG2
binds and hydrolyzes GTP and GTP binding inhibits the
transamidation activity [3]. Under normal physiological condi-
tions, due to low calcium levels and high GTP levels, TG2 is a
latent enzyme with respect to transamidation activity [4,5]. Under
pathological conditions with high intracellular calcium and
decreased GTP reserves, increases in TG2 transamidation activity
likely occur [6]. A significant outcome of calcium binding is that
concurrent with activation, TG2 undergoes an extraordinary
conformational change that results in an extended structure [7]. In
contrast, in the GTP bound state, TG2 exists in a compact and
closed structure that decreases the accessibility of the active site
[8,9]. Therefore, calcium binding and GTP binding inversely
regulate the conformational state of TG2, as well as the
transamidation activity.
In addition to its enzymatic activities, TG2 can also act as a
scaffold or linker protein to mediate protein-protein interactions
both extracellularly [10,11] and intracellularly [2,12,13]. TG2
contributes to the organization of the extracellular matrix via
binding to fibronectin and mediating its interaction with collagen
and integrins [10,14,15]. These interactions primarily play a role
in migration and wound healing independent of its transamidation
activity or GTP binding ability [16]. In the nucleus, TG2 interacts
with c-Jun and this interaction can interfere with c-Jun binding to
AP-1 binding sites on promoters. This leads to decreased matrix
metalloproteinase-9 (MMP-9) expression [13]. TG2 co-immuno-
precipitates with Rb protein, and E2F transcriptional activity is
significantly suppressed in cells expressing nuclear localized wild-
type TG2 [12]. Recently it was shown that wild type TG2
suppresses cytochrome c promoter reporter activity when mutant
huntingtin is present [17]. Further, TG2 interacts with HIF-1b,
the constitutively expressed subunit of HIF-1 (Hypoxia inducible
factor-1) transcription factor, and attenuates hypoxic signaling in
SH-SY5Y cells independent of its transamidating activity [2]. In
addition there are HREs in the TG2 promoter [18] and TG2 is
upregulated in stroke models [19,20,21,22]. These findings
indicate that TG2 is a hypoxia responsive protein that may
modulate transcriptional activity of hypoxia responsive genes via
its interaction with HIF-1b.
Previously it was shown that nuclear localization of TG2 can
play a role in cell survival in a transamidation inactive state [12].
Increased nuclear localization of TG2 was detected in SH-SY5Y
cells in response to hypoxia concurrent with protection against
oxygen-glucose deprivation (OGD)-induced cell death [2]. In a
mouse model, nuclear translocation of exogenously expressed
human TG2 was observed after middle cerebral artery ligation
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These findings suggest that the cellular localization of TG2 may be
important in determining whether TG2 will facilitate or
ameliorate cell death processes, particularly in response to OGD.
In previous studies, it was shown that R580A mutation of
human TG2 (TG2-R580A) prevents GTP binding. Rat TG2 with
this same mutation (R579A) exhibited higher transamidation
activity at basal conditions compared to wild type TG2 [23].
Additionally, R579A exhibited an open conformation due to
absence of GTP binding which is the stabilizing factor for the
closed structure [9]. Therefore, forms of TG2 that are deficient in
GTP binding can show high basal transamidation activity. In
another study, it was found that R580L and R580K mutants of
human TG2 cause increased cell death in response to serum
deprivation [24]. These data suggest that the absence of GTP
binding can potentiate cell death under stress conditions.
However, it is still not known whether the detrimental affect of
TG2-R580A is due to its high transamidation activity, lack of GTP
binding ability or its open conformational state.
In this study, we investigated the role of intracellular localization,
transamidation activity and different conformations of TG2 in its
protective effect in OGD induced cell death. In a clonal striatal cell
model, TG2 was not translocated into the nucleus in response to
OGD and neither wild type TG2 nor a transamidating inactive
form (TG2-C277S) protected against OGD induced cell death.
Further, TG2-R580A significantly potentiated OGD induced cell
death, an effect that was negated by targeting it to the nucleus.
Treatment of cells expressing wild type TG2, TG2-C277S or TG2-
R580A with Compound 4d (Cp4d), a reversible TG2 inhibitor
(inhibits transamidation activity) [25] did not cause any protection
or potentiation of OGD induced cell death. Intriguingly, treatment
of cells expressing either wild type TG2 or TG2-C277S with NC9
(Compound9 in[26]),anirreversibleTG2inhibitorthat reactswith
the active site of TG2 and likely stabilizes the protein in an open
conformation [26], resulted in a significant increase in OGD-
induced cell death. However, NC9 did not cause any protection or
potentiation of OGD induced cell death in cells expressing TG2-
R580A or in naı ¨ve cells. These findings suggest that cellular
localization (cytosolic or nuclear) and conformational states are key
factors in determining whether TG2 facilitates or ameliorates cell
death processes.
Materials and Methods
Generation of stable cell lines and cell culture
Naı ¨ve, temperature-sensitive immortalized mouse striatal cells
were a generous gift from Dr. Marcy E. MacDonald [27]. Cells are
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(Invitrogen, Life Technologies, Inc) with 8% fetal bovine serum
(Invitrogen, Life Technologies, Inc.) supplemented with 2 mM L-
glutamine (Invitrogen, Life Technologies, Inc.), 100 mg/ml strep-
tomycin (Invitrogen, Life Technologies, Inc.) and 100 units/ml
penicillin (Invitrogen, Life Technologies, Inc) at the permissive
temperature 33uC. The generation of striatal cells that inducibly
express human wild type TG2 was described previously [28].
Striatal cells that inducibly express either TG2-C277S or TG2-
R580A were established and characterized as described previously
[28].TG2 expressioninthesestablytransfectedcellswasinducedby
incubation with 2 mg/mL doxycycline (Sigma Aldrich, Inc). Naı ¨ve
cells were also incubated with 2 mg/mL doxycycline as a control.
In vitro transglutaminase assay
In vitro transamidation activity was measured in cell extracts
using a modification of a previously described procedure [29].
Fifty microliters of assay buffer containing 2 mM CaCl2 was used
for each reaction. Two hundred fifty microliters of 0.25 M NaOH
was added to each tube for termination of reactions. Protein
concentration of the supernatant was determined using the
bicinchoninic acid assay with bovine serum albumin as a standard,
and transamidation activity was calculated after background
subtraction as nanomoles of putrescine incorporated per milligram
of protein per hour.
In situ transglutaminase assay
In situ transglutaminase activity was quantified by determining
the incorporation of 5-(biotinamido) pentylamine into protein
substrates. We used a microplate assay as described previously [4]
with modifications. The cells were labeled for 2 h with 1 mM 5-
(biotinamido) pentylamine (Pierce). Forty micrograms of protein
was loaded into each well of a 96-well microtiter plate (Falcon-BD
Biosciences) in a final volume of 50 mL and the plates were
incubated overnight at 4uC. One hundred microliters of HRP-
conjugated neutravidin (1:1000) in 1% BSA and 0.01% Tween 20
in borate saline buffer was used for detecting biotinylated
proteins and readings were taken at 492 nm on a microplate
spectrophotometer.
Cell treatment paradigm
Cells were transferred to serum free DMEM media (Invitrogen,
Life Technologies, Inc) for the hypoxic treatments or glucose free
DMEM media (Invitrogen, Life Technologies, Inc) for OGD. For
hypoxic treatments, cells were incubated in a humidified hypoxic
glove box (Coy Laboratory Products) containing 5% CO2 and
0.1% O2 at 33uC for the indicated times (16–36 h). Control cells
were incubated in serum free media in a humidified incubator
containing 5% CO2 and ambient O2 at 33uC. Cp4d is a reversible
transglutaminase inhibitor [25] and NC9 (Compound 9 in Figure 4
of [26]) is an irreversible transglutaminase inhibitor. Both
compounds potently inhibited the in situ transamidation activity
of TG2, however, NC9 reacts with the active site of TG2 and
likely stabilizes an open conformation [26]. For cell death
measurements, cells were incubated with or without 20mM Cp4d
or 10 mM NC9, which are the highest concentrations that can be
used without toxicity, For 36 h in OGD conditions as described
above. DMSO was used as vehicle (0.04% v/v) in the treatment
media. The control group was treated with DMSO alone.
Cp4d and NC9 were tested individually to determine their
ability to inhibit in situ transamidation activity in the stable cell
lines. For these experiments, cells were incubated in the absence or
presence of Cp4d or NC9 and with our without 5mM ionomycin
for 3 h prior to in situ transamidation activity measures as
described above.
Co-immunoprecipitation
Cells were washed once with ice-cold phosphate buffer saline
(PBS) and collected in lysis buffer (10 mM Tris-HCl pH 7.5,
200 mM NaCl, 1 mM EGTA, 1 mM EDTA, 0.75% NP-40 with
0.1 mM phenylmethylsulfonyl fluoride, and 10 mg/ml of each of
aprotinin, leupeptin, and pepstatin A). Protein concentrations of
the samples were determined by using the bicinchoninic acid
assay. Magnetic beads (M-280 Dynabeads, Invitrogen) that were
coupled with anti-rabbit IgG were washed 3 times with 2% BSA in
PBS. The beads were blocked with 5% ovalbumin in PBS for 2 h
at 4uC on an orbital shaker. One microgram of rabbit anti-mouse
HIF-1b antibody per sample was added to the beads that were
then incubated overnight at 4uC on an orbital shaker. The beads
were then washed 3 times with 1% ovalbumin in PBS. One
hundred micrograms of each cell lysate were added to the beads
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beads were washed with wash buffer (350 mM NaCl, 0.2%
Triton-X in PBS) 4 times. Proteins bound on the beads were
collected by boiling for 10 min in 26 stop buffer. The samples
were analyzed by western blotting.
Cellular fractionation
Cells were fractionated as described previously [12] with
modifications. Cells were washed once and harvested in ice cold
PBS. The cell pellets were resuspended in lysis buffer (10 mM Tris,
pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.05% Nonidet P-40, 1 mM
EGTA, 0.1 mM phenylmethylsulfonyl fluoride, 10 mg/ml of each
of aprotinin, leupeptin, and pepstatin A). Cell lysates were
centrifuged at 3806g for 5 min at 4uC. The supernatants were
collected as the cytosolic portion and further centrifuged at 1006g
for 1 h to clear the cytosolic fractions. The crude nuclei were spun
at 12006g for 10 min at 4uC through a 0.6 M sucrose cushion
and the enriched nuclei were collected in the pellet. The proteins
were visualized by immunoblotting.
Immunoblotting
Cell lysates were blotted as described [12] with modifications.
The blots were probed overnight at 4uC with anti-TG2 antibody
TG100 (Neomarkers) (1:2000) or anti-HIF-1a antibody (Calbio-
chem Inc) (1:1000), anti-HIF-1b (Novus Biologicals) (1:2000), anti-
histone (Chemicon Inc.) (1:10.000), anti-a tubulin (Sigma-Aldrich
Inc.) (1:10.000) or anti-actin (Chemicon Inc.) (1:5000) antibodies
in 5% non-fat dry milk in TBST. The membranes were rinsed
three times for 30 min with TBST and incubated with HRP-
conjugated secondary antibody (1:2000) in 5% non-fat dry milk in
TBST for 2 h at room temperature. Lastly, the blots were rinsed
three times for 1 h with TBST and developed with a chemilumi-
nescence solution as previously described [30].
HRE-Luciferase reporter assay
Cells were transiently transfected with firefly luciferase vector
pGL3-SV40–6HRE, a generous gift from Dr. Carine Michiels.
Co-transfection with renilla luciferase vector was carried out using
Lipofectamine 2000 reagent according to manufacturer’s direc-
tions. After 24 h, cells were transferred to serum free media and
incubated under hypoxic conditions for 16 h. Control cells were
kept in serum free media under ambient O2 conditions. Luciferase
activity was measured by using the Dual-Luciferase Reporter
Assay System Kit (Promega) according to the manufacturer’s
protocol.
Lactate Dehydrogenase (LDH) Release Assay
Cells were transferred to glucose free media and incubated in a
humidified hypoxic glove box at 0.1% O2,5 %C O 2 at 33uC for
36 h. Control samples were kept in serum free media in a
humidified chamber at 5% CO2,3 3 uC and ambient O2 level.
LDH release was measured by using an LDH release assay kit
(Roche) according to the manufacturer’s protocol.
Calcein AM cell viability assay
Cells were transferred to glucose free media and incubated in
a humidified hypoxic glove box at 0.1% O2,5 %C O 2 at 33uC
for 24 h. At the end of the treatment, cells were washed once
with phosphate buffer saline (PBS) and Calcein AM in PBS was
added to the wells to a final concentration of 5 mM. The cells
were kept at 33uC for 30 min and fluorescence readings were
taken using a 490 nm excitation filter and a 520 emission filter
(BioTek Synergy HT Multi-Detection Microplate Reader). The
fluorescence intensity is proportional to the number of viable
cells.
Lentivirus production and transduction
Wild type TG2, TG2-R580A and the nuclear localization signal
tagged TG2-R580A (NLS-R580A) were cloned into FIGB
lentiviral vector. TG2 expression was driven by a CMV promoter,
with GFP downstream under the control of IRES [31]. The
lentiviral vector backbone was a generous gift from Dr. C.
Proschel at the University of Rochester. Viral particles were made
in HEK 293T cells (ATCC, cat. no. CRL-11268) by cotransfec-
tion of the lentiviral vector, pMD2.G (VSVG-envelope) and
psPAX2 (packaging components) plasmids (Addgene.org). Viral
particles were concentrated 20 times by centrifugation of cell
media at .50,0006g for 2 h at 4uC. The pellet was resuspended
in 1% BSA in sterile PBS.
Cells were plated at 75% confluency on 24-well plates in low
serum media (DMEM with 2% FBS) and after 24 h viral particles
(30–35 ml) were added directly to the media of the cells. Cells were
incubated overnight in the humidified incubator at 5% CO2 at
37uC, the restrictive temperature that prevents proliferation, and
kept for 5–6 days to allow for expression of the transduced
constructs. The media was half-replaced with fresh media every 3
days. Expressions of constructs were confirmed by immunocyto-
chemistry and western blot analysis.
Immunocytochemistry
Naı ¨ve cells were plated at 75% confluency on coverslips in low
serum media and transduced as described above. After 6–7 days of
infection, cells were fixed with 4% paraformaldehyde for 15 min,
washed once with PBS and kept in 0.1 M glycine for 5 min. The
cells were permeabilized with 0.2% Triton-X in PBS and blocked
with 2% BSA in PBS for 2 h at room temperature. Cells were
incubated with anti-human TG2 antibody TG100 (1:500 dilution
in PBS) overnight. The next day, cells were washed twice with PBS
and incubated with FITC-conjugated secondary antibody for 2 h
at room temperature. The cells were washed twice with PBS and
incubated with Hoechst nuclear stain (1:2000) for 15 min at room
temperature. After rinsing twice with PBS, the coverslips were
mounted on glass and viewed using an Axiovert inverted
microscope with Axiocam-XMR camera (Carl Zeiss, Hamamatsu
ORCA-ER digital camera). Hoechst staining was used to
determine the total number of cells. The FITC positive cells
represent lentiviral expression of TG2. The merged images of
FITC and Hoechst staining were used to determine the percent of
cells that were transduced.
Statistics
All data were expressed as mean +/2 SEM and were plotted
using Graphpad Instat software. The means were compared with
ANOVA and Tukey’s test in all the figures except the in situ
transamidation activity experiment performed with Cp4d in which
unpaired t-test was used.
Results
Stable expression of TG2 constructs
To determine the relative expression of the TG2 constructs in
the stably transfected cells, lysates were immunoblotted with anti-
human TG2 antibody which only recognizes exogenous TG2 after
induction by doxycycline treatment. The blots in Fig. 1A show
that the stably transfected cells express TG2, TG2-C277S and
TG2-R580A at equivalent levels. The apparent molecular weight
of TG2 was ,77 kDa. Approximately 30–40% of the total
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PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16665Figure 1. Characterization of striatal stable cell lines. A, Representative immunoblots of cell lysates from striatal cells stably expressing wild
type TG2, TG2-C277S (C277S) or TG2-R580A (R580A) mutants. Top panel: Lysates were blotted for TG2. Bottom panel: Lysates were blotted for actin as
loading control. B, In vitro transamidating activities of stable striatal cell lines. TG2-R580A cells show significantly greater in vitro transamidating
activity compared to naı ¨ve and C277S cells. (N=5) C, In situ transamidating activity of striatal stable cell lines. TG2-R580A (R580A) cells show
significantly higher in situ transamidating activity than all the other cell lines. (N=3) Results are shown as mean +/2 standard error, **p,0.01,
***p,0.005.
doi:10.1371/journal.pone.0016665.g001
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stable cell lines (data not shown). Immunoblotting revealed that
the TG2 transgene expression in the stable cell lines was
substantially higher than the levels of endogenous TG2 in mouse
or human brain lysates (data not shown). However, the brain
lysates contains many cell types other than neurons and the
expression level of TG2 in the different cell types is highly variable.
Therefore it is difficult to compare expression levels in the cell lines
and in neuronal populations in vivo.
In vitro transglutaminase activity of stable cell lysates
To determine the total transamidation activity of the stably
transfected cell lines, an in vitro transglutaminase assay was used.
Cell lysates were collected from each cell line and activity was
measured in the presence of 2 mM calcium. This concentration of
calcium was determined to give maximum in vitro transamidating
activity in these cell lines (data not shown). The in vitro
transamidating activities of each cell line are shown as pmol/
mg/h (Fig. 1B). TG2 overexpressing cells showed 3-fold higher in
vitro transamidating activity compared to naı ¨ve cells. TG2-C277S
(a transamidating-inactive form) overexpressing cells showed
approximately equal transamidating activity as the naı ¨ve control
cells. TG2-R580A overexpressing cells showed significantly higher
(5-fold) in vitro transamidating activity compared to naı ¨ve control.
These results indicate that all the stable cell lines show the
expected in vitro transamidating activities.
In situ transglutaminase activity of stable cells
To determine intracellular transamidating activities of the stably
transfected cell lines, an in situ transglutaminase assay was used.
Cells were labeled for 2 h with 1 mM 5-(biotinamido) pentylamine
and incorporation of this substrate to the intracellular proteins was
measured under basal conditions (Fig. 1C). TG2 overexpressing
cells showed a 2 fold increase in intracellular transamidating
activity. There was no increase in the intracellular transamidating
activity of TG2-C277S overexpressing cells due to the lack of
catalytic activity. The TG2-R580A cells showed 8-fold higher in
situ transamidating activity compared to naı ¨ve control cells which
was expected due to the more open conformation of the protein
and the lack of inhibition by intracellular GTP [9,23].
The interaction of TG2 with HIF-1b
The interaction of TG2 with HIF-1b was described previously
[2]. To further characterize the striatal cell lines and to test
whether TG2-R580A can interact with HIF-1b, co-immunopre-
cipitation experiments were performed. HIF-1b was pulled down
from cell lysates and the precipitates were blotted for TG2 (Fig. 2A
top panel). TG2, TG2-C277S, and TG2-R580A were detectable
in the immunoprecipitated cell lysates under both normoxic and
hypoxic conditions. There was no detectable TG2 in the negative
control sample (sham) in which the immunoprecipitation was
performed with magnetic beads but without the HIF-1b antibody.
The immunoprecipitation blot was reprobed with HIF-1b
antibody to show the presence of HIF-1b in the immunoprecip-
itates (Fig. 2A bottom panel). Five percent of the total protein
amount used for immunoprecipitation, was blotted for TG2
(Fig. 2B top panel) and HIF-1b (Fig. 2B bottom panel) as input
controls. These data suggest that the interaction of TG2 with HIF-
1b is independent of its transamidation activity or GTP binding
ability since both TG2-C277S (transamidating inactive) and TG2-
R580A (GTP binding deficient) mutants interact with HIF-1b.
Intracellular localization of TG2, TG2-C277S and TG2-
R580A in stable cells
It has been shown that nuclear TG2 levels increase in SH-SY5Y
cells in response to hypoxic treatment [2] and TG2 translocates to
the nucleus in mouse brain after MCAL [20]. To determine if
TG2, TG2-C277S or TG2-R580A localize to the nucleus in this
cell line in response to OGD, the cells were fractionated into
cytosolic and nuclear portions and immunoblotted for TG2
(Fig. 3A–C, top panels). Fractions were also blotted with total
histone (nuclear protein) and a-tubulin (cytosolic protein) anti-
bodies to determine the purity of the fractions. As expected,
histones were only detectable in the nuclear fractions and a-
tubulin was only present in cytosolic fractions. Nuclear levels of
wild type TG2 did not change after OGD treatment in TG2-
expressing cells (Fig. 3A). However, there were decreases in the
nuclear levels of TG2-C277S (Fig. 3B, ,70% less) and TG2-
R580A (Fig. 3C, ,66% less) as well as the cytosolic levels of TG2-
R580A after OGD treatment. These data indicate that in striatal
Figure 2. Interaction of TG2 with HIF-1b.A , Representative immunoblots showing the coimmunoprecipitation of TG2 with HIF-1b. Top panel:
HIF-1b was immunoprecipitated from the cell lysates of stable striatal cell lines and blotted for TG2. Bottom panel: The top blot was stripped and re-
probed for HIF-1b. Wild type TG2, and the mutants TG2-C277S (C277S), TG2-R580A (R580A) immunoprecipitated with HIF-1b. B, 5% of the total
amount of cell lysate used for immunoprecipitation was blotted for TG2 and HIF-1b.
doi:10.1371/journal.pone.0016665.g002
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to OGD.
HRE reporter activity in response to hypoxia
Cells were transferred to serum free media and maintained at
0.1% O2 in a humidified hypoxic chamber prior to collecting
lysates and blotting with a HIF-1a antibody (Fig. 4A top panel).
HIF-1a protein was not detectable under normoxic conditions, as
expected, and the levels of HIF-1a were equivalent in all the cell
lines after hypoxic treatment. An actin blot is shown as a loading
control. The effects of TG2, TG2-C277S and TG2-R580A on
HRE reporter activity were also measured (Fig. 4B). There was no
significant difference in HRE luciferase activity of TG2 and TG2-
C277S overexpressing cells compared to naı ¨ve control cells.
However, cells overexpressing TG2-R580A showed significantly
higher HRE reporter activity than naı ¨ve control cells. This
experiment was repeated using at least one other independent
subclone of each cell line, and the results were approximately the
same (data not shown).
TG2-R580A potentiates OGD induced cell death
To test the effect of TG2-R580A in OGD-induced cell death,
LDH release assay was performed subsequent to 36 h of OGD.
Naı ¨ve, TG2 and TG2-C277S cells showed 4-fold and TG2-
R580A cells showed 7-fold increases in LDH release after OGD
treatment compared to their relative normoxic controls. Interest-
ingly, TG2-R580A cells showed significantly greater fold LDH
release (1.5- to 1.7-fold) than naı ¨ve, TG2 and TG2-C277S cells
after OGD treatment (Fig. 5A). These data suggest that TG2-
R580A expression facilitates OGD-induced cell death in these
cells. This experiment was repeated using another independent
subclone of each cell line, and the result was approximately the
same. We also carried out the same experiment in the absence of
Doxycyclin, which induces exogenous TG2 expression. When we
did not induce TG2 expression OGD-induced cell death in the
individual stable cell lines and the naı ¨ve cells no differences in the
extent of cell death were observed (data not shown).
To further examine the effects of the different TG2 constructs
on OGD-induced cell death, a viability assay with Calcein AM
was carried out. This assay measures the intracellular esterase
activity present in viable cells and thus the readings represent the
amount of viable cells, which is normalized to the normoxic
conditions. After 24 h of OGD treatment, naı ¨ve cells showed 45%
cell viability. The viability of TG2-R580A cells was significantly
reduced to 15% after OGD treatment (Fig. 5B).
Targeting TG2-R580A to the nucleus counteracts the
detrimental effect of TG2-R580A in OGD
To test whether nuclear localization of TG2-R580A alters its
detrimental effects, naı ¨ve cells were transduced with lentiviral
constructs that express wild type TG2, TG2-R580A or NLS-
R580A. The cells were transduced with control virus (Fig 6A: a, b,
c, d) and TG2-expressing virus (Fig 6A: e, f, g, h) and after 5–6
days the cells were fixed and probed with a TG2 antibody that
recognizes only exogenously expressed human TG2. The merged
image (Fig. 6A: h) shows that .95% of cells are transduced with
the TG2 virus. In order to compare the expression of TG2, TG2-
R580A and NLS-R580A, transduced cell lysates were blotted with
Figure 3. Subcellular localization of TG2, TG2-C277S and TG2-R580A. A, B, C, Immunoblots showing subcellular localization of TG2, TG2-
C277S (C277S) and TG2-R580A (R580A). Striatal stable cells were fractionated into nuclear and cytosolic compartments with or without OGD
treatment. Cell lysates were blotted for TG2 (1
st panels), histones (2
nd panels), tubulin (3
rd panels). Histone and tubulin blots show the purity of the
fractions. TG2 blots show that there is no increase in the nuclear TG2 levels after OGD treatment in any of the cell lines.
doi:10.1371/journal.pone.0016665.g003
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loading control (Fig. 6B, bottom panel). All TG2 constructs were
expressed at comparable levels. The nuclear localization of NLS-
R580A was confirmed by previous studies performed in our lab
[5].
Transduced cells were treated with OGD and cell death was
measured. Both TG2 (60%) and TG2-R580A (44%) transduced
cells showed significant induction of LDH release compared to
control (Fig 6C). However, cell death in the NLS-R580A
transduced cells was similar to that observed in control cells
indicating that localization of TG2 to the nucleus prevents it from
acting in a pro-death capacity.
Cp4d (a reversible TG2 transamidation inhibitor) does
not prevent the detrimental effect of TG2-R580A in
ischemic cell death
To test whether the high basal transamidation activity of TG2-
R580A is necessary for its ability to potentiate cell death, stably
transfected cells were treated with OGD with or without 20mM
Cp4d. This concentration was the highest non-toxic concentration
of Cp4d that we could use. To demonstrate that Cp4d inhibits in
situ transamidation activity of TG2 and TG2-R580A, cells were
incubated with or without 5mM ionomycin in the absence or
presence of 20mM Cp4d (Fig. 7A). Ionomycin increases intracel-
lular Ca
2+ levels and resulted in a significant increase in
intracellular transamidation activity of TG2 and TG2-R580A. In
situ transamidation activity is expressed as fold increase relative to
the corresponding stable cell line without ionomycin treatment
(Fig. 7A). Cp4d significantly attenuated the ionomycin-induced
increase in the transamidation activity of both TG2 and TG2-
R580A. We also confirmed by immunocytochemistry that TG2 is
not externalized in this cell model (data not shown). Therefore we
can conclude that Cp4d inhibits the elevation of in situ
transamidation activity in response to ionomycin by acting
intracellularly. LDH release was measured to detect cell death in
stable cell lines in the absence and presence of 20 mM Cp4d. Fold
LDH release was expressed relative to the corresponding stable
cell line maintained under normoxic conditions (Fig. 7B). Naı ¨ve,
TG2 and TG2-C277S cells showed a 6–8 fold increase, while
TG2-R580A cells showed a 16 fold increase in LDH release in
response to OGD treatment. Cp4d treatment did not result in any
changes in LDH release in TG2, TG2-C277S and TG2-R580A
Figure 4. HRE luciferase assay. A, Immunoblots of the cell lysates from striatal stable cells showing the HIF-1a protein stabilization after 16 h of
0.1% O2.( 2) represents naı ¨ve cells maintained in normoxic conditions. Lysates were also probed for actin as a loading control. B, Fold HRE luciferase
activity of stable striatal cells after 16 h of 0.1% O2. TG2-R580A (R580A) cells showed significantly higher HRE activation than the other cell lines.
(N=8) Results are shown as mean +/2 SE, *p,0.05.
doi:10.1371/journal.pone.0016665.g004
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basal LDH release in normoxic conditions. Given that inhibition
of the transamidating activity of TG2-R580A did not attenuate its
effect on OGD-induced cell death, it is likely that the potentiation
of cell death by TG2-R580A cells in response to OGD treatment is
transamidation independent.
We also tested an irreversible transglutaminase inhibitor NC9
which reacts with the active site of TG2 [26] and likely stabilizes
the protein in open conformation [7]. NC9 significantly inhibits
the in situ transamidation activity of TG2 and TG2-R580A
(Fig. 8A). NC9 was used at the highest non-toxic concentration
and at this concentration it was fully inhibitory. LDH release was
measured and expressed as fold increase relative to the
corresponding stable cell line maintained at normoxic conditions
(Fig. 8B). Naı ¨ve, TG2 and TG2-C277S cells showed ,4- to 5-fold
increase, and TG2-R580A expressing cells showed ,12-fold
increase in LDH release after OGD treatment. NC9, which
inhibits the transamidation activity of TG2, did not have any affect
on basal LDH release in stable cells in control normoxic
conditions. Interestingly, both TG2 (2.65-fold) and TG2-C277S
(2.5-fold) expressing cells showed a significant increase in OGD-
induced LDH release in response to NC9 treatment. However,
NC9 treatment did not have any effect on OGD-induced
LDH release in naı ¨ve cells or cells expressing TG2-R580A
(Figure 8B).
Discussion
In this study, we investigated how the transamidation activity
state, cellular localization and conformation of TG2 impact its
effect on OGD induced cell death. We used TG2-C277S as a
transamidation inactive form and TG2-R580A as a GTP-binding
deficient form having greater transamidating activity. We also
used Cp4d, a reversible transglutaminase inhibitor [25] to
determine the role of transamidation activity of TG2 in how it
regulates OGD induced cell death.
Figure 5. OGD-induced cell death. A, Fold LDH release after 36 h of OGD at 0.1% O2. TG2-R580A (R580A) cells showed significantly higher fold
LDH release than other cell lines after OGD treatment. (N=6) B, Calcein AM cell viability assay after 24 h OGD treatment at 0.1% O2. TG2-R580A
(R580A) cells showed significantly lower cell viability after OGD treatment. (N=6) Results are shown as mean +/2 SE, *p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0016665.g005
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16665Figure 6. OGD-induced cell death with NLS tagged R580A. A, Immunocytochemistry of naı ¨ve striatal neurons that were infected with a
control or wild type TG2 lentiviral construct. Panels a, b, c, and d represent the naı ¨ve cell transduced with control lentivirus. Panels e, f, g, and h
represent naı ¨ve cells transduced with wild type TG2. Immunocytochemistry was performed with a TG2 antibody that was recognized by a FITC-
conjugated mouse secondary antibody. From left to right: phase, TG2 staining labeled by FITC, Hoechst nuclear staining, merge of FITC and Hoechst
staining. B, Immunoblots of cell lysates from naı ¨ve cells transduced with control, TG2, TG2-R580A (R580A) and NLS tagged R580A (NLS-R580A)
lentiviruses. Actin blot is shown for loading controls. C, Fold LDH release in lentivirus infected striatal cells after 36 hr of OGD at 0.1% O2. Both TG2
and TG2-R580A (R580A) expressing cells showed significant increases in fold LDH release after OGD treatment, while NLS-R580A showed similar fold
LDH release amount as the control. (N=8) Results are shown as mean +/2 SEM, ***p,0.001.
doi:10.1371/journal.pone.0016665.g006
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were measured and confirmed to be as predicted according to
previous studies [8,9]. We also demonstrated that, as previously
observed in SH-SY5Y cells [2], wild-type TG2 and TG2-C277S
co-immunoprecipitated with HIF-1b. We extended these findings
by demonstrating that TG2-R580A interacts with HIF-1b to
Figure 7. OGD-induced cell death with Cp4d Treatment. A, Fold increase in in situ transamidation activity in response to ionomycin treatment
in the absence (2) or presence (+)o f2 0 mM Cp4d (Reversible TG2 inhibitor) in comparison to basal in situ transamidation activity of the corresponding
cell line. TG2-R580A cells showed potentiation of in situ transamidation activity with 5mM ionomycin treatment which was inhibited by Cp4d
treatment (N=3) B, Fold LDH release after 36 h of OGD treatment at 0.1% O2 in the absence (2) or presence (+)o f2 0mM Cp4d (Reversible TG2
inhibitor) in comparison to percent LDH release amount of corresponding cell line at normoxia. None of the cell lines showed significant changes in
fold LDH release with Cp4d treatment. (N=3) Results are shown as mean +/2 SE, * p,0.05. **p,0.01.
doi:10.1371/journal.pone.0016665.g007
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PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16665Figure 8. OGD-induced cell death with NC9 treatment. A, Fold in situ transamidation activity with ionomycin treatment in the absence (2)o r
presence (+)o f1 0mM NC9 (Irreversible TG2 inhibitor) in comparison to basal in situ transamidation activity of the corresponding cell line. TG2 cells
(12 fold) and TG2-R580A cells (19 fold) showed potentiation of in situ transamidation activity with 5mM ionomycin treatment which was inhibited
100% by NC9 treatment (N=3). B, Fold LDH release after 36 h of OGD treatment at 0.1% O2 in the absence (2) or presence (+)o f1 0mM NC9 (TG2
inhibitor) in comparison to percent LDH release amount of corresponding cell line at normoxia. TG2 and TG2-C277S (C277S) cells showed significant
increases in fold LDH release with NC9 treatment. (N=4) Results are shown as mean +/2 SE, *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0016665.g008
Cytosolic TG2-R580A Enhances Ischemic Cell Death
PLoS ONE | www.plosone.org 11 January 2011 | Volume 6 | Issue 1 | e16665approximately the same extent as wild type TG2 and TG2-C277S.
Therefore, TG2 interacts with HIF-1b independent of its
transamidation activity state or GTP binding ability.
In SH-SY5Y cells and cortical neurons TG2 translocates to the
nucleus and attenuates HRE reporter activity under hypoxic
conditions [2]. In addition, in a mouse stroke model in which
human TG2 was expressed in neurons, translocation of TG2 into
the nucleus was observed [20]. In contrast, TG2 did not localize to
the nucleus in these clonal striatal cells in response to hypoxia and
we did not observe a suppression effect on HRE reporter activity.
In fact, decreases in the nuclear levels of TG2-C277S and TG2-
R580A, as well as total TG2-R580A protein level were observed
after OGD treatment. Binding of GTP is required for TG2 to
adopt the most compact and protease resistant conformation
[3,9,32] and therefore TG2-R580A may be more susceptible to
proteolysis which may be a contributing factor to the OGD-
induced decreases in TG2-R580A levels. Expression of TG2-
R580A resulted in a slight but significant increase in HRE activity
compared to naı ¨ve control cells while TG2 and TG2-C277S
expressing cells did not show any difference. These findings
indicate that the interaction of TG2 with HIF1b is not sufficient to
mediate its ability to suppress HRE activity or facilitate its
translocation to the nucleus in response to hypoxia. Further, the
hypoxic-induced translocation of TG2 to the nucleus is cell type
specific and thus likely to be dependent on other proteins or
factors. The mechanism of nuclear translocation of TG2 is still
unknown. It has been suggested that TG2 has two NLS sequences
[17], therefore can interact with importin a-3 and may be
localized to nucleus via this interaction [33]. Finally, these findings
support the hypothesis that the suppression of HRE activation by
TG2 is dependent on its nuclear localization.
TG2 can both ameliorate and facilitate cell death processes in a
cell type and stress dependent manner [34,35], and it has been
previously suggested that transamidating activity and subcellular
localization are contributing factors in determining how TG2
affects cell viability. When the stressor increased the transamidat-
ing activity of TG2 in SH-SY5Y cells, TG2 facilitated apoptosis.
In contrast, if the stressor did not result in increased transamidat-
ing activity, TG2 ameliorated cell death [29]. In HEK cells,
nuclear-targeted TG2-C277S protected against thapsigargin-
induced cell death [12]. In this study, TG2-R580A expression
significantly increased OGD-induced cell death compared to the
expression of TG2 or TG2-C277S, or naı ¨ve cells. However
targeting TG2-R580A to the nucleus (NLS-R580A) abrogated this
response. Previously, in HEK cells, TG2-R580A increased cell
death in response to thapsigargin treatment while nuclear targeted
TG2-R580A did not show the same detrimental effect [5]. These
findings strongly suggest that nuclear localization of TG2 is
protective and results in increased cell survival. Given the fact that
TG2-R580A exhibits higher basal transamidating activity and
adopts a less compact conformation, [9,23] we next investigated
what role each of these variables play in determining the effects of
TG2-R580A on OGD-induced cell death.
In order to determine whether transamidation activity is critical
for the detrimental role of TG2-R580A, we used the reversible
TG2 transamidation inhibitor Cp4d [25] which significantly
inhibited in situ transamidation activity of TG2 and TG2-R580A
cells. However, Cp4d treatment did not result in any potentiation
or suppression of cell death in any of the stable cell lines in
response to OGD. Therefore, we can conclude that the cell death
affect of TG2-R580A is transamidation independent.
We also tested an irreversible TG2 transamidating inhibitor
NC9 [26]. NC9 bears an electrophilic group designed to react with
the active site thiol and strongly inhibited the in situ transamidation
activity of TG2-R580A in stable cells. NC9 binds to the active site
of TG2 irreversibly [26] and therefore likely stabilizes the protein
in an open, but inactive conformation [7]. Intriguingly, treatment
of cells expressing TG2 or TG2-C277S with inhibitor NC9
resulted in a significant increase in OGD-induced cell death.
However, NC9 had no effect on OGD-induced cell death in naı ¨ve
cells or TG2-R580A expressing cells. Given that NC9 increased
OGD-induced cell death in the presence of TG2-C277S (a
transamidation inactive mutant), it is possible that NC9 is
electrophilic enough to react with the nucleophilic Ser residue in
the active site of TG2-C277S [26] which would result in a more
extended conformation as well. On the other hand, TG2-R580A,
which already showed significantly increased OGD-induced cell
death, exhibited neither an attenuation nor potentiation of cell
death in response to NC9. It has been suggested that TG2-R580A
is already in a more open conformation [9], and therefore it can be
speculated that although NC9 reacts with the active site of TG2-
R580A and inhibits its transamidating activity, it does not
significantly extend the conformation of the molecule. Therefore
the potentiation of OGD-induced cell death in TG2-R580A cells
is not dependent on high transamidation activity which can be
inhibited by both irreversible and reversible inhibitors.
Overall, these data suggest that the pro-death role of TG2-
R580A is not due to its high basal transamidation activity, but it is
possible that the more open conformation of TG2 in the cytosol
results in facilitation of cell death processes. Given the dramatically
different conformations in the GTP-bound state (closed and
compact) and the activated state (open and extended) [7,8,9], it
can be suggested that they may play an important role in regulating
TG2’sinteractionwithotherproteins,andthatthesenon-enzymatic
interactions may be critical in determining the function of TG2,
either facilitating or ameliorating cell death processes.
Interestingly Protein 4.2, which is the only catalytically inactive
member of transglutaminase family, is primarily a linker protein
interacting with several membrane proteins (B3, ankyrin, spectrin,
CD47) in erythrocytes [36,37,38]. Based on TG2 structural
studies, it has been suggested that Protein 4.2 might require an
open conformation to interact with other protein partners like B3
(Band 3) on the plasma membrane [39]. Given the similarities
between TG2 and Protein 4.2, it is tantalizing to speculate that the
primary function of TG2 in cell death/survival processes is to act
as a scaffold or linker protein rather than as an enzyme and that
the conformational changes it undergoes dictate its binding
partners and thus different functions.
In conclusion, these results indicate that when TG2 is in the
cytosol in a more extended conformation it facilitates OGD-
induced cell death independent of its transamidation activity.
Additionally, hypoxic-induced relocalization of TG2 to the
nucleus is cell type specific and plays primarily a protective role.
Overall these findings provide important new insights into the
differential effects of TG2 on cell survival and cell death processes.
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